EA201790434A1 - Модуляторы каналов - Google Patents

Модуляторы каналов

Info

Publication number
EA201790434A1
EA201790434A1 EA201790434A EA201790434A EA201790434A1 EA 201790434 A1 EA201790434 A1 EA 201790434A1 EA 201790434 A EA201790434 A EA 201790434A EA 201790434 A EA201790434 A EA 201790434A EA 201790434 A1 EA201790434 A1 EA 201790434A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulators
channel modulators
pannexin
channel
disorders
Prior art date
Application number
EA201790434A
Other languages
English (en)
Inventor
Колин Ричард Грин
Йери Ким
Энтони Филлипс
Бредфорд Джеймс Дафт
Original Assignee
Окленд Юнисервисиз Лимитед
Окунексас Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55351389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790434(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Окленд Юнисервисиз Лимитед, Окунексас Терапьютикс, Инк. filed Critical Окленд Юнисервисиз Лимитед
Publication of EA201790434A1 publication Critical patent/EA201790434A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Abstract

Изобретение относится к композициям и изделиям, содержащим модуляторы коннексина, модуляторы паннексина, модуляторы щелевых контактов, модуляторы гемиканалов и модуляторы паннексиновых каналов, и их применению, одних или в комбинации, для лечения глазных и других нарушений.
EA201790434A 2014-08-22 2015-08-21 Модуляторы каналов EA201790434A1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NZ62863014 2014-08-22
US201462080217P 2014-11-14 2014-11-14
US201462085226P 2014-11-26 2014-11-26
US201562146128P 2015-04-10 2015-04-10
US201562147488P 2015-04-14 2015-04-14
NZ70967315 2015-07-02
PCT/US2015/046425 WO2016029191A2 (en) 2014-08-22 2015-08-21 Channel modulators

Publications (1)

Publication Number Publication Date
EA201790434A1 true EA201790434A1 (ru) 2017-07-31

Family

ID=55351389

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790434A EA201790434A1 (ru) 2014-08-22 2015-08-21 Модуляторы каналов

Country Status (8)

Country Link
US (5) US10465188B2 (ru)
EP (1) EP3183346A4 (ru)
JP (2) JP6683686B2 (ru)
CN (2) CN114010788A (ru)
AU (3) AU2015305269B2 (ru)
CA (1) CA2958879A1 (ru)
EA (1) EA201790434A1 (ru)
WO (1) WO2016029191A2 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833614B1 (en) 2012-06-22 2017-12-05 Nevro Corp. Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods
HK1243457A1 (zh) * 2014-08-22 2018-07-13 Auckland Uniservices Ltd 通道調節劑
KR102643821B1 (ko) 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
CN105536093B (zh) * 2016-03-10 2019-05-03 京东方科技集团股份有限公司 智能输液系统以及使用智能输液系统的输液方法
WO2017192620A2 (en) * 2016-05-03 2017-11-09 University Of Auckland Novel peptides and peptidomimetics
JP7082115B2 (ja) * 2016-06-02 2022-06-07 エイディーエス セラピューティクス リミテッド ライアビリティ カンパニー 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
EP3512528A4 (en) * 2016-09-14 2020-05-13 Agency for Science, Technology and Research MODULATION OF THE TJP1 EXPRESSION FOR REGULATING THE REGENERATION OF HEART CELLS
US11466069B2 (en) 2017-04-28 2022-10-11 Auckland Uniservices Limited Methods of treatment and novel constructs
US11324799B2 (en) 2017-05-05 2022-05-10 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
CN108976288B (zh) * 2017-06-05 2021-09-21 复旦大学 基于野生型穿膜肽penetratin的亲脂性衍生物
US11344603B2 (en) * 2017-07-19 2022-05-31 Auckland Uniservices Limited Cytokine modulation
WO2019060409A1 (en) * 2017-09-19 2019-03-28 The Cleveland Clinic Foundation INHIBITION OF CONNEXIN 46 TO TREAT A GLIOBLASTOMA AND OTHER STATES
CN108066744A (zh) * 2017-12-29 2018-05-25 于海龙 细胞连接蛋白43模拟肽Gap19在制备治疗脑出血药物中的用途
JP2021519632A (ja) 2018-03-29 2021-08-12 ネヴロ コーポレイション ２型糖尿病を含む血糖異常を治療する、および／またはＨｂＡ１ｃレベルを低下させるための治療的調節、ならびに関連するシステムおよび方法
US11464672B2 (en) * 2018-06-01 2022-10-11 Aurora Tears Technology, Inc. Systems and methods for generating and applying biomimicry tear films
US11253395B2 (en) 2018-06-01 2022-02-22 Aurora Tears Technology, Inc. Systems and methods for generating and applying biomimicry tear films
AU2019337636A1 (en) * 2018-09-12 2021-03-25 Xequel Bio, Inc. Nanoparticle formulations and methods of use for alpha connexin c-terminal peptides
CN109799216B (zh) * 2018-12-29 2021-11-12 佛山科学技术学院 一种基于吲哚箐绿纳米的荧光oct双模成像方法和装置
EP3920969A4 (en) * 2019-02-04 2022-11-30 Alamab Therapeutics, Inc. CONNEXIN 43 ANTIBODIES AND THEIR USE
CN209330231U (zh) * 2019-02-15 2019-08-30 广州视源电子科技股份有限公司 网络摄像机及录播系统
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
JP7393780B2 (ja) * 2019-08-19 2023-12-07 学校法人順天堂 ギャップ結合機能制御剤のスクリーニング方法
CA3154499A1 (en) * 2019-09-13 2021-03-18 Auckland Uniservices Limited Compositions and methods for rescuing retinal and choroidal structure and function
WO2021067775A1 (en) * 2019-10-02 2021-04-08 Alamab Therapeutics, Inc. Anto-connexin antibody formulations
CN110859826B (zh) * 2019-12-09 2022-04-05 深圳先进技术研究院 一种脑肿瘤靶向的仿生载药纳米颗粒及其制备方法和用途
AU2020454040A1 (en) * 2020-06-19 2023-02-09 Endogena Therapeutics, Inc. New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium
US11912764B2 (en) 2020-07-31 2024-02-27 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
TWI769506B (zh) * 2020-08-26 2022-07-01 長庚大學 用以治療因發炎體激活所致相關疾病的方法
WO2023105417A1 (en) * 2021-12-06 2023-06-15 Breye Therapeutics Aps Danegaptide formulation for applicatoin in the eye
WO2023212727A1 (en) * 2022-04-29 2023-11-02 Board Of Regents, The University Of Texas System Compositions and methods for treating eye diseases
US20240024348A1 (en) * 2022-07-21 2024-01-25 Ophthalmic Therapeutic Innovation Methods and compositions for the treatment of glaucoma and related conditions
CN116655740B (zh) * 2023-05-26 2023-12-08 海南大学 一种赭曲霉毒素a的抗原模拟肽及编码核酸分子和应用

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
JPH0539594Y2 (ru) 1988-08-05 1993-10-07
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
GB2273932A (en) 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
EP0673374B1 (en) 1992-12-11 2000-03-01 Smithkline Beecham Plc Pharmaceutical composition containing bicyclic type compounds
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US20030148968A1 (en) 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6566339B1 (en) 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
PT871730E (pt) 1995-10-11 2004-11-30 Chiron Corp Combinacao de pdgf, kgf, igf e igfbp para cicatrizacao de ferimentos
DE69731302T3 (de) 1996-07-22 2011-01-20 Renovo Ltd. Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden
CA2273203A1 (en) 1996-12-02 1998-06-11 Dyad Pharmaceutical Corporation Antisense inhibition of human adhesion molecules
GB9702943D0 (en) 1997-02-13 1997-04-02 Univ Manchester Wound healing
WO1999007844A2 (en) 1997-08-07 1999-02-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods and compositions for treatment of restenosis
CA2313348A1 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6855505B2 (en) 1998-06-26 2005-02-15 Renovo Limited Method for quantifying TGF-β
ES2239846T5 (es) 1998-07-30 2011-03-04 The Government Of The United States Of America, As Repres. By The Secretary Of Health And Human Services, Nat. Inst. Of Health Mejora de la curación de heridas mediante la timosina beta-4.
CA2347916A1 (en) 1998-11-06 2000-05-18 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
ATE300959T1 (de) 1999-01-27 2005-08-15 Becker David Dr Formulierungen enthaltend antisense nukleotide spezifisch für connexine
GB9903598D0 (en) 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
ES2436624T3 (es) 1999-05-14 2014-01-03 Arbor Vita Corporation Péptidos o análogos de péptidos para modulación de la fijación de una proteína PDZ y una proteína PL
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
EP1938799B1 (en) 2000-03-10 2013-05-08 Insite Vision Incorporated Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof
CA2425662A1 (en) 2000-10-18 2002-04-25 Children's Medical Center Corporation Osteopontin-coated surfaces and methods of use
AU2002239336A1 (en) 2000-11-10 2002-06-03 Arbor Vita Corporation Molecular interactions in hematopoietic cells
WO2002064193A2 (en) 2000-12-14 2002-08-22 Georgia Tech Research Corporation Microneedle devices and production thereof
IL156955A0 (en) 2001-01-17 2004-02-08 Genecraft Inc Binding domain-immunoglobulin fusion proteins
WO2002088370A2 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Autogene nucleic acids encoding a secretable rna polymerase
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US20050119211A1 (en) 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
CN1827766B (zh) 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
US6685971B2 (en) 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
EP1443951A4 (en) 2001-08-03 2006-05-03 Arbor Vita Corp MOLECULAR INTERACTIONS IN CELLS
WO2003032964A2 (en) 2001-10-17 2003-04-24 University Of Wales College Of Medecine Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
EP1469875A1 (en) 2002-01-29 2004-10-27 Wyeth Compositions and methods for modulating connexin hemichannels
JP2003238441A (ja) 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
AU2003234613A1 (en) 2002-05-15 2003-12-02 Seul, Kyung, Hwan Method of modulating angiogenesis
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
WO2005000223A2 (en) 2003-06-04 2005-01-06 Children's Medical Center Corporation Method of treating retinopathies and disorders associated with blood vessel loss
WO2005000382A2 (en) 2003-06-04 2005-01-06 Georgia Tech Research Corporation Drilling microneedle device
EP1514929A1 (en) 2003-09-12 2005-03-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense oligonucleotides for prevention of metastasis formation of cancer cells
EP2311949A3 (en) * 2003-12-03 2012-11-21 Coda Therapeutics (NZ) Ltd Antisense compounds targeted to connexins and methods of use thereof
DE102004027422A1 (de) 2004-06-04 2005-12-29 Boehringer Ingelheim Microparts Gmbh Vorrichtung zur Aufnahme von Blut und Abtrennung von Blutbestandteilen
GB0420888D0 (en) 2004-09-20 2004-10-20 Photopharmica Ltd Compounds and uses
US7627938B2 (en) 2004-10-15 2009-12-08 Board Of Regents, The Univeristy Of Texas System Tapered hollow metallic microneedle array assembly and method of making and using the same
US7097776B2 (en) 2004-10-22 2006-08-29 Hewlett-Packard Development Company, L.P. Method of fabricating microneedles
BRPI0519737A2 (pt) 2004-12-21 2009-01-27 Musc Found For Res Dev composiÇÕes e mÉtodos para promover a cura de feridas e a regeneraÇço de tecidos
EP2662088A3 (en) * 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
EP1910297B1 (en) 2005-07-11 2016-05-25 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
EP1919500A2 (en) 2005-07-13 2008-05-14 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
US20080159979A1 (en) 2005-08-04 2008-07-03 Moore Emma E Treatment of wounds using il-17b
FR2891149B1 (fr) 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
WO2007068252A2 (en) 2005-12-16 2007-06-21 Arla Foods Amba Bovine osteopontin formulations for the improvement of the wound healing process
US7918814B2 (en) 2006-05-02 2011-04-05 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
AU2007254159B2 (en) 2006-05-19 2013-07-04 Mako Surgical Corp. System and method for verifying calibration of a surgical device
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
JP5960944B2 (ja) 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
EP2543378A1 (en) 2006-12-11 2013-01-09 Coda Therapeutics, INC. Anticonnexin polynucleotides as impaired wound healing compositions
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
JP2010520181A (ja) 2007-03-02 2010-06-10 ナショナル・ユニバーシティ・オブ・アイルランド・ゴルウェイ 心血管疾患の予測および治療のためのオステオポンチン
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
DK2166845T3 (en) * 2007-06-21 2016-02-01 Musc Found For Res Dev ALFA-connexin C-terminal (ACT) peptides FOR THE TREATMENT OF AGE-related macular degeneration
CN102105492A (zh) 2007-12-11 2011-06-22 科达治疗公司 受损伤口愈合的组合物和治疗
US20100279921A1 (en) 2007-12-11 2010-11-04 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
JP2011507862A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
WO2009085268A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
AU2008343755A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
WO2009085269A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
JP2011507858A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 整形外科状態の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた、抗コネキシンペプチドの使用
CA2710227A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of surgical adhesions
AU2008343841A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
WO2009085275A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
JP2011508605A (ja) 2008-01-07 2011-03-17 コーダ セラピューティクス， インコーポレイテッド 創傷治癒組成物および治療
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
WO2009102931A1 (en) 2008-02-15 2009-08-20 Alcon Research, Ltd. Rnai-mediated inhibition of connexin 43 for treatment of iop-related conditions
EP2307546A1 (en) 2008-06-04 2011-04-13 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
WO2009147441A2 (en) 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
CA2726878A1 (en) 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
JP2011524912A (ja) 2008-06-18 2011-09-08 インスパイアー ファーマシューティカルズ，インコーポレイティド Ｒｈｏキナーゼ阻害化合物の眼科用製剤
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2760562C (en) 2009-05-01 2016-07-19 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US20110016548A1 (en) * 2009-07-16 2011-01-20 University Of Southern California Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems
CA2782625A1 (en) 2009-12-03 2011-06-09 Proximagen Ltd Treatment of allodynia and hyperalgesia
WO2011072091A1 (en) * 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
CN104736709A (zh) 2012-03-27 2015-06-24 科达治疗公司 基于钙粘蛋白调节的组合物和治疗
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
EP2870148A1 (en) 2012-07-03 2015-05-13 Proximagen Limited Pro-drug compounds
CN105263494A (zh) 2013-03-15 2016-01-20 爱瑞制药公司 联合治疗

Also Published As

Publication number Publication date
US20200239889A1 (en) 2020-07-30
US20160177298A1 (en) 2016-06-23
US11401516B2 (en) 2022-08-02
AU2021282410A1 (en) 2021-12-23
JP6683686B2 (ja) 2020-04-22
CN107109410B (zh) 2021-11-02
JP2017526687A (ja) 2017-09-14
AU2015305269A1 (en) 2017-03-23
US20210115445A1 (en) 2021-04-22
US20200263175A1 (en) 2020-08-20
WO2016029191A3 (en) 2016-08-18
CA2958879A1 (en) 2016-02-25
AU2015305269B2 (en) 2021-12-23
WO2016029191A2 (en) 2016-02-25
US10465188B2 (en) 2019-11-05
EP3183346A4 (en) 2018-10-24
US20230174980A1 (en) 2023-06-08
AU2024201060A1 (en) 2024-03-14
EP3183346A2 (en) 2017-06-28
CN114010788A (zh) 2022-02-08
CN107109410A (zh) 2017-08-29
JP2023022154A (ja) 2023-02-14

Similar Documents

Publication Publication Date Title
EA201790434A1 (ru) Модуляторы каналов
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890908A1 (ru) Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
MX2015012334A (es) Metodos y composiciones para el control de malezas.
GB2541571A (en) Pharmaceutical compositions
NZ755605A (en) Compositions for modulating tau expression
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201790802A1 (ru) Соединения против tnf
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.